Program
liposomal doxorubicin
Also written as “PLD”, “Doxorubicin Hydrochloride Liposome Injection” and “Pegylated liposomal doxorubicin”.
Its studies are mostly in Ovarian Neoplasms · Breast Neoplasms · Multiple Myeloma · Carcinoma, Ovarian Epithelial · Endometrial Neoplasms, led by 16 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Johnson & Johnson | 90 open or running | phase 3since Apr 29, 2004 | Apr 29, 2004 | none ahead |
| Merck | 60 open or running | phase 4since Jan 21, 2008 | Dec 15, 2005 | none ahead |
| CSPC Pharmaceutical Group | 20 open or running | phase 2since Dec 11, 2017 | Dec 11, 2017 | none ahead |
| Imunon | 20 open or running | phase 2since Nov 1, 2011 | Jun 5, 2003 | none ahead |
| Oncotherapeutics | 20 open or running | phase 2since Aug 26, 2008 | Aug 26, 2008 | none ahead |
| TTY Biopharm | 20 open or running | phase 2since Aug 31, 2010 | Aug 31, 2010 | none ahead |
| ayana-pharma-ltd | 10 open or running | phase 1since Sep 17, 2018 | Sep 17, 2018 | none ahead |
| azaya-therapeutics-inc | 10 open or running | phase 1since Oct 19, 2012 | Oct 19, 2012 | none ahead |
| Baxter Healthcare | 10 open or running | phase 1since Sep 29, 2022 | Sep 29, 2022 | none ahead |
| Dr. Reddy's Laboratories | 10 open or running | phase 1since Sep 22, 2014 | Sep 22, 2014 | none ahead |
| Luye Pharma Group | 10 open or running | phase 1since Oct 18, 2023 | Oct 18, 2023 | none ahead |
| Sarah Cannon Research Institute | 10 open or running | phase 2since Mar 13, 2006 | Mar 13, 2006 | none ahead |
| Shanghai Fudan-Zhangjiang Bio-Pharmaceutical | 10 open or running | phase 1since Aug 31, 2014 | Aug 31, 2014 | none ahead |
| shenzhen-kangzhe-pharmaceutical-co-ltd | 10 open or running | phase 1since Feb 10, 2022 | Feb 10, 2022 | none ahead |
| Takeda | 10 open or running | phase 2since Jan 28, 2008 | Jan 28, 2008 | none ahead |
| Teva Pharmaceutical Industries | 10 open or running | phase 2since Jul 8, 2008 | Jul 8, 2008 | none ahead |
Also a collaborator on its studies: Eisai, Novotech (Australia) Pty, Lambda Therapeutic Research, MDS Pharma Services, Essex Pharma, Tibotec Therapeutics, a Division of Ortho Biotech Products, L.P., USA, Ortho Biotech, Tibotec Pharmaceutical, Sequus Pharmaceuticals and Prologue Research International.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 19 studies since Jun 5, 2003.
- Oct 11, 2011Phase 2 study in Breast NeoplasmsTTY Biopharm · NCT01451580 · 47 enrolled · Taiwan
- Nov 1, 2011Phase 2 study in Colonic NeoplasmsImunon · NCT01464593 · 2 enrolled · United States
- Oct 19, 2012azaya-therapeutics-inc’s first study: phase 1 study in Ovarian NeoplasmsNew to azaya-therapeutics-incazaya-therapeutics-inc · NCT01715168 · 40 enrolled · United States, Canada
- Mar 18, 2013Phase 3 study in Carcinoma, Ovarian EpithelialJohnson & Johnson · NCT01840943 · 32 enrolled · China
- Mar 5, 2014Phase 1 study in NeoplasmsJohnson & Johnson · NCT02081495 · 35 enrolled · United States, Belgium, Canada and more
- Jul 30, 2014Phase 2 study in Multiple MyelomaOncotherapeutics · NCT02206425 · 45 enrolled · United States
- Aug 31, 2014Shanghai Fudan-Zhangjiang Bio-Pharmaceutical’s first study: phase 1 study in Ovarian NeoplasmsNew to Shanghai Fudan-Zhangjiang Bio-PharmaceuticalShanghai Fudan-Zhangjiang Bio-Pharmaceutical · NCT02237690 · 30 enrolled · China
- Sep 22, 2014Dr. Reddy's Laboratories’ first study: phase 1 study in Ovarian Epithelial Cancer RecurrentNew to Dr. Reddy's LaboratoriesDr. Reddy's Laboratories · NCT02260544 · 49 enrolled · India
- Dec 11, 2017CSPC Pharmaceutical Group’s first study: phase 2 study in Poorly Differentiated Thyroid CarcinomaNew to CSPC Pharmaceutical GroupCSPC Pharmaceutical Group · NCT03387943 · 30 enrolled · China
- Sep 17, 2018ayana-pharma-ltd’s first study: phase 1 study in Ovarian NeoplasmsNew to ayana-pharma-ltdayana-pharma-ltd · NCT03681548 · 52 enrolled · India
- Jul 2, 2020No phase study in BioequivalenceCSPC Pharmaceutical Group · NCT04460820 · 32 enrolled · China
- Feb 10, 2022shenzhen-kangzhe-pharmaceutical-co-ltd’s first study: phase 1 study in Breast NeoplasmsNew to shenzhen-kangzhe-pharmaceutical-co-ltdshenzhen-kangzhe-pharmaceutical-co-ltd · NCT05273944 · 80 enrolled · China
- Sep 29, 2022Baxter Healthcare’s first study: phase 1 study in Ovarian NeoplasmsNew to Baxter HealthcareBaxter Healthcare · NCT05567601 · 36 enrolled · India
- Oct 18, 2023Luye Pharma Group’s first study: phase 1 study in Advanced Breast CancerNew to Luye Pharma GroupLuye Pharma Group · NCT06098599 · 48 enrolled · China
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 33 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT06098599Advanced Breast Cancer · China | 1 | Completed | Luye Pharma Group | Feb 9, 2023 | 48 |
| NCT05567601Ovarian Neoplasms · India | 1 | Completed | Baxter Healthcare | Jun 21, 2024 | 36 |
| NCT05273944Breast Neoplasms · China | 1 | UNKNOWN | shenzhen-kangzhe-pharmaceutical-co-ltd | Mar 31, 2022 | 80 |
| NCT04460820Bioequivalence · China | – | Completed | CSPC Pharmaceutical Group | Dec 23, 2019 | 32 |
| NCT03681548Ovarian Neoplasms · India | 1 | Completed | ayana-pharma-ltd | Feb 8, 2019 | 52 |
| NCT03387943Poorly Differentiated Thyroid Carcinoma · China | 2 | UNKNOWN | CSPC Pharmaceutical Group | Dec 31, 2018 | 30 |
| NCT02260544Ovarian Epithelial Cancer Recurrent · India | 1 | Completed | Dr. Reddy's Laboratories | Apr 2015 | 49 |
| NCT02237690Ovarian Neoplasms · China | 1 | Completed | Shanghai Fudan-Zhangjiang Bio-Pharmaceutical | Aug 2015 | 30 |
| NCT02206425Multiple Myeloma · United States | 2 | Completed | Oncotherapeutics | Jan 19, 2018 | 45 |
| NCT02081495Neoplasms · United States, Belgium, Canada and more | 1 | Completed | Johnson & Johnson | Nov 2015 | 35 |
| NCT01840943Carcinoma, Ovarian Epithelial · China | 3 | Terminated | Johnson & Johnson | May 2014 | 32 |
| NCT01715168Ovarian Neoplasms · United States, Canada | 1 | UNKNOWN | azaya-therapeutics-inc | Oct 2015 | 40 |
| NCT01464593Colonic Neoplasms · United States | 2 | Terminated | Imunon | May 2013 | 2 |
| NCT01451580Breast Neoplasms · Taiwan | 2 | UNKNOWN | TTY Biopharm | 47 | |
| NCT01210768Breast Neoplasms · Taiwan | 2 | UNKNOWN | TTY Biopharm | Oct 31, 2022 | 254 |
| NCT00779285Breast Neoplasms | 4 | Terminated | Merck | Aug 2006 | 1 |
| NCT00742404Multiple Myeloma · United States | 2 | UNKNOWN | Oncotherapeutics | Jul 2010 | 35 |
| NCT00712881Breast Neoplasms · Austria, Belgium, France and more | 2 | Completed | Teva Pharmaceutical Industries | Sep 17, 2015 | 126 |
| NCT00706953Multiple Myeloma | 2 | Withdrawn | Johnson & Johnson | Jun 2010 | 0 |
| NCT00727961Ovarian Neoplasms | 4 | Completed | Merck | Jan 10, 2008 | 58 |
| NCT00698451Ovarian Neoplasms · United States | 2 | Completed | Johnson & Johnson | Oct 2010 | 54 |
| NCT00687440Breast Neoplasms | 2 | Completed | Merck | Oct 24, 2008 | 27 |
| NCT00653952Ovarian Neoplasms | 3 | Terminated | Johnson & Johnson | 220 | |
| NCT00610792Ovarian Neoplasms · Italy, Switzerland | 2 | Withdrawn | Takeda | Sep 2009 | 91 |
| NCT00604968Breast Neoplasms | 4 | Terminated | Merck | Oct 16, 2009 | 25 |
| NCT00561743Multiple Myeloma | 2 | Completed | Johnson & Johnson | May 2007 | 50 |
| NCT00550771Breast Neoplasms | 2 | Completed | Merck | Aug 23, 2010 | 181 |
| NCT00303108Breast Neoplasms · United States | 2 | Completed | Sarah Cannon Research Institute | Mar 2010 | 136 |
| NCT00266799Breast Neoplasms | 3 | Completed | Merck | Sep 29, 2010 | 210 |
| NCT00097981Multiple Myeloma · United States | 3 | Completed | Johnson & Johnson | Oct 2007 | 225 |
| NCT00091442Breast Neoplasms · United States, Bulgaria, Estonia and more | 3 | Completed | Johnson & Johnson | Dec 2008 | 751 |
| NCT00082095Breast Neoplasms · United States | 3 | Terminated | Johnson & Johnson | Dec 2005 | 62 |
| NCT00061867Prostatic Neoplasms · United States | 1 | Completed | Imunon |
How it is read
Names in the registry
- “PLD”, 4 entries
- “Doxorubicin Hydrochloride Liposome Injection”, 4 entries
- “Pegylated liposomal doxorubicin”, 3 entries
- “Pegylated Liposomal Doxorubicin (PLD)”, 2 entries
- “liposomal doxorubicin”, 2 entries
Conditions, from the studies’ own filings
- Ovarian Neoplasms, 16 studies
- Breast Neoplasms, 13 studies
- Multiple Myeloma, 5 studies
- Carcinoma, Ovarian Epithelial, 3 studies
- Endometrial Neoplasms, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.